详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Matching-Adjusted Indirect Comparison (MAIC): Entrectinib versus Crizotinib in Asian Patients with ROS1+NSCLC

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

机构： [1]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China [2]Zhejiang Canc Hosp, Hangzhou, Peoples R China [3]Dept Med Oncol, Harbin, Peoples R China [4]Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China [5]Sichuan Canc Hosp, Chengdu, Peoples R China [6]Peking Univ Canc Hosp & Inst, Beijing, Peoples R China [7]Shanghai Roche Pharmaceut Ltd, Shanghai, Peoples R China [8]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China

出处：

ISSN：

关键词： ROS1+NSCLC Asian patients Matching-Adjusted Indirect Comparison

语种：

WOS：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

JCR分区：

出版当年[2023]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

最新[2023]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 21 最新[2023版] 16.5 最新五年平均 21 出版当年[2023版] 16.5 出版当年五年平均 20.4 出版前一年[2022版]

第一作者：

第一作者机构： [1]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Repotrectinib in patients (pts) from Asia and China with ROS1 fusion- positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial [2]BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-rearranged NSCLC: a Case Report. [3]First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data. [4]AB-106治疗ROS1阳性NSCLC受试者的Ⅱ期研究（TRUST研究） [5]BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-rearranged NSCLC: a Case Report. [6]Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma [7]Osilodrostat treatment in patients with Cushing's disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4) [8]Entrectinib in Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours [9]Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study. [10]Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma.